1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Benaki, D. Zikos, C. Evangelou, A. Livaniou, E. Vlassi, M. Mikros, E. Pelecanou, M. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochem.Biophys.Res.Commun. BBRCA9 0146 0006-291X 329 152 160 10.1016/j.bbrc.2005.01.100 15721287 Solution structure of humanin, a peptide against Alzheimer's disease-related neurotoxicity. 2005 10.2210/pdb1y32/pdb pdb_00001y32 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 2691.264 Humanin 1 syn polymer no no MAPRGFSCLLLLTSEIDLPVKRRA MAPRGFSCLLLLTSEIDLPVKRRA A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n database_2 pdbx_nmr_software pdbx_nmr_spectrometer pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2005-02-22 1 1 2008-04-30 1 2 2011-07-13 1 3 2022-03-02 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name _pdbx_nmr_spectrometer.model RCSB Y RCSB 2004-11-23 REL REL Humanin was prepared by Fmoc-solid phase synthesis on -Cl-trityl-amidomethyl polystyrene resin. The peptide was purified to 95% with semi-preparative RP-HPLC and suitably characterized. Evangelou, A., Zikos, C., Livaniou, E., and Evangelatos, G.P. (2004) High-yield, solid-phase synthesis of humanin, an Alzheimer s disease associated, novel 24-mer peptide which contains a difficult sequence, J. Peptide Science 10, 631-635. sample This structure was determined using standard 2D homonuclear techniques. structures with the lowest energy 300 14 2D NOESY 2D TOCSY 2D NOESY 2D TOCSY 60 microM sodium azide 2.7 ambient 298 K 60 microM sodium azide 2.7 ambient 280 K simulated annealing torsion angle dynamics 1 closest to the average NMR studies of humanin were carried out in H2O/TFE-d3 7:3 solution containing 60 microM NaN3 at 280 and 298 K. The concentration of the sample was 1.7 mM and the pH of the solution was 2.7 (uncorrected for the presence of TFE). H2O/TFE-d3 7:3 solution containing 60 microM NaN3 Bruker collection XwinNMR 2.6 Bruker processing XwinNMR 2.6 Goddard data analysis Sparky 3 Brunger structure solution CNS 1.1 Brunger refinement CNS 1.1 500 Bruker AVANCE MET 1 n 1 MET 1 A ALA 2 n 2 ALA 2 A PRO 3 n 3 PRO 3 A ARG 4 n 4 ARG 4 A GLY 5 n 5 GLY 5 A PHE 6 n 6 PHE 6 A SER 7 n 7 SER 7 A CYS 8 n 8 CYS 8 A LEU 9 n 9 LEU 9 A LEU 10 n 10 LEU 10 A LEU 11 n 11 LEU 11 A LEU 12 n 12 LEU 12 A THR 13 n 13 THR 13 A SER 14 n 14 SER 14 A GLU 15 n 15 GLU 15 A ILE 16 n 16 ILE 16 A ASP 17 n 17 ASP 17 A LEU 18 n 18 LEU 18 A PRO 19 n 19 PRO 19 A VAL 20 n 20 VAL 20 A LYS 21 n 21 LYS 21 A ARG 22 n 22 ARG 22 A ARG 23 n 23 ARG 23 A ALA 24 n 24 ALA 24 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A ALA 2 60.12 88.34 1 A SER 14 -130.50 -46.43 1 A LYS 21 -178.02 -39.67 2 A ARG 22 -177.54 43.46 2 A ARG 23 -155.88 -76.39 3 A SER 14 -130.66 -46.24 4 A SER 14 -132.01 -46.26 4 A LYS 21 57.73 -174.92 4 A ARG 22 -131.50 -45.93 4 A ARG 23 -173.86 -51.85 5 A LYS 21 -152.92 -49.64 5 A ARG 22 -154.68 -72.27 6 A ALA 2 61.48 153.55 6 A SER 14 -134.47 -46.30 7 A ALA 2 60.98 92.87 7 A SER 14 -131.23 -46.29 7 A LYS 21 63.20 -78.04 7 A ARG 22 64.19 -79.43 7 A ARG 23 -177.91 -177.99 8 A ALA 2 60.54 162.74 8 A ARG 23 -155.18 -70.33 10 A ALA 2 -166.33 88.21 10 A LYS 21 60.38 80.30 11 A LEU 10 -54.89 -75.77 11 A SER 14 -135.96 -46.27 11 A VAL 20 43.18 77.65 11 A LYS 21 69.19 103.66 11 A ARG 22 -148.11 -63.58 11 A ARG 23 59.58 104.62 12 A VAL 20 -92.50 33.08 12 A ARG 22 -135.62 -56.46 13 A LYS 21 176.20 156.66 13 A ARG 22 -152.55 -64.14 13 A ARG 23 -164.12 -71.00 14 A VAL 20 -93.68 32.56 14 A ARG 22 -94.39 46.05 NMR structure of humanin in 30% TFE solution 1 N N A PRO 3 A PRO 3 HELX_P A ILE 16 A ILE 16 1 1 14 UNKNOWN FUNCTION Humanin, NMR solution structure, Alzheimer's disease, neuroprotection, UNKNOWN FUNCTION HUNIN_HUMAN UNP 1 1 Q8IVG9 MAPRGFSCLLLLTSEIDLPVKRRA 1 24 1Y32 1 24 Q8IVG9 A 1 1 24